GW Pharmaceuticals (GWPH) Upcoming Challenge, Veeva Systems (VEEV) Cloud Above Wall Street's View |
Posted: November 26, 2014 |
Crown Equity Holdings Inc. (CRWE) CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites. One of the primary goals of the CRWE Network is to offer business owners the power of consumer targeting advertisements on a local and national scale. The CRWE Network has reached the 1486th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada. CRWE has recently included the City of Riverside, CA ( www.riverside.crwe-pr.com ) to the CRWE Network. Riverside is a city in Riverside County, California, located in the Inland Empire metropolitan area. It is the county seat of the eponymous county and named for its location beside the Santa Ana River. Riverside lies 60 miles east of Los Angeles. The Pacific Ocean is about 35 miles to the southwest Riverside had an estimated population in 2013 (U.S. Census Bureau) of approximately 316,619, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday. CRWE plans to have full national coverage of all U.S and Canada businesses in the future on its CRWE-PR Business Directory, which will be integrated to the CRWE Network. Online video is gaining strength as a source for content marketing. Strategic plans are being developed for CRWE’s division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company. The CRWE-PR Finance website ( www.finance.crwe-pr.com ) allows CRWE the instant distribution of information to the entire CRWE Network. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com ** GW Pharmaceuticals plc (GWPH) Keep a close eye on GWPH. The company will report on Tuesday December 2nd, 2014 its fourth quarter and year-end financial results for the period ending 30 September, 2014. GWPH has recently commenced a Phase 2/3 clinical trial of Epidiolex(R) (cannabidiol or CBD) for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. According to the Principal Investigator of the study, initial trials of Epidiolex have shown promising signals of efficacy in children that suffer with Dravet syndrome for which there remains a substantial unmet medical need GWPH's Epidiolex is the first plant-based CBD medicine to be studied in a FDA-authorized, placebo-controlled trial and the company looks forward to working with leading pediatric epilepsy centers across the U.S. to advance this clinical program as rapidly as possible. GWPH anticipates commencing an additional Phase 3 trial in Dravet syndrome in the first quarter of 2015 in parallel with part two of the first Phase 2/3 trial. The company also expects to commence two Phase 3 clinical trials in Lennox-Gastaut syndrome in the first quarter of 2015. GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GWPH commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 26 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is intended to support the submission of a New Drug Application for Sativex in cancer pain with the FDA and in other markets around the world. GWPH has a deep pipeline of additional cannabinoid product candidates, including Epidiolex(R) in the treatment of childhood epilepsy, which has received Fast Track Designation from the FDA for Dravet syndrome as well as Orphan Drug Designations from the FDA in both the treatment of Dravet syndrome and Lennox-Gastaut syndrome and Orphan Designation from the European Medicines Agency for Dravet syndrome. GWPH‘s product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. More about at GW Pharmaceuticals plc (GWPH) about www.gwpharm.com ** Veeva Systems Inc. (VEEV) VEEV delivered strong financial results across the board and the business added over $40 million of cash to the balance sheet in the quarter. For its third quarter fiscal 2015, VEEV posted total revenues of $83.8 million, a 52% increase year over year, non-GAAP net income of $13.7 million, a 77% increase compared to the same period the prior year, and topped Wall Street expectations with a non-GAAP fully diluted net income per share of $0.09, better than the Capital IQ Consensus Estimate of $0.08 per share. According to its financial outlook for its full year fiscal 2015, VEEV expects total revenues to be in the range of $310.7 million to $311.7 million, non-GAAP operating income in the range of $83.1 million to $84.1 million, and non-GAAP fully diluted net income per share is expected to be in the range of $0.33 to $0.34. VEEV is a leader in cloud-based software for the global life sciences industry. More about Veeva Systems Inc. (VEEV) at www.veeva.com. ** Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
|
||||||||||||||||||||||||||||||||||||||||||
|